A5070451207- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Vascular Tumors and Angiosarcomas
- Retinoids in leukemia and cellular processes
- Monoclonal and Polyclonal Antibodies Research
- Histiocytic Disorders and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Fungal Infections and Studies
- Microtubule and mitosis dynamics
- Mast cells and histamine
- Genetic Neurodegenerative Diseases
- Glycosylation and Glycoproteins Research
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2017-2024
The Ohio State University
2017-2024
The Ohio State University Wexner Medical Center
2017-2024
Quest Diagnostics (United States)
2010-2024
St Bartholomew's Hospital
2024
University of Minnesota Rochester
2022
Koç University
2022
Gangneung Asan Hospital
2022
University of Pittsburgh Medical Center
2022
Roche (Switzerland)
2022
We examined the outcome of patients with newly diagnosed acute promyelocytic leukemia (APL) treated all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) or without gemtuzumab ozogamicin (GO) but traditional cytotoxic chemotherapy.
Abstract Purpose: To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated imatinib. Experimental Design: We analyzed results quantitative PCR in 280 CML phase who achieved complete cytogenetic remission imatinib (117 after IFN-α failure 163 previously untreated). Median follow-up was 31 months (range, 3-52 months). Results: BCR-ABL/ABL ratio before start therapy 39.44 0.252-170.53). A major (BCR-ABL/ABL...
Purpose Although most patients with chronic myeloid leukemia (CML) in phase respond well to front-line therapy imatinib, some do not achieve the desirable end point, and others may eventually lose response or are intolerant. Patients Methods newly diagnosed CML were treated nilotinib 400 mg twice daily on an empty stomach as initial therapy. Results Among 51 observed for at least 3 months, 50 (98%) achieved a complete cytogenetic remission (CCyR), 39 (76%) major molecular (MMR). Responses...
Purpose Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial patients with CML in early phase. Patients and Methods newly diagnosed phase were randomly assigned to receive 100 mg once daily or 50 twice therapy. Results Among observed at least 3 months, 49 (98%) achieved a complete cytogenetic response (CCyR), 41 (82%) major molecular (MMR). Responses occurred rapidly, 94% achieving CCyR by...
We performed a multi-institutional retrospective analysis of the morphologic features, immunophenotype, cytogenetics, and BCR-ABL transcript characterization cases Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML). compared these with documented chronic myelogenous in blast crisis (CML-MBC). Patients Ph+ AML were less likely to have splenomegaly or peripheral basophilia had lower bone marrow cellularity myeloid/erythroid ratios than patients CML-MBC. Additional specific...